Skip to main
NBTX

Nanobiotix SA (NBTX) Stock Forecast & Price Target

Nanobiotix SA (NBTX) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Nanobiotix is a promising biotechnology company with a unique and innovative approach to treating cancer through nanotechnology. The company's partnership with JNJ and recent positive data updates from their nanoenhancer NBTXR3 demonstrate potential for success in large commercial markets. However, there are risks such as execution, financial, and regulatory setbacks that could negatively impact the company's growth. Considering potential milestone payments and discounted cash flow analysis, we have set a price target of $46/share for the company.

Bears say

Nanobiotix is a clinical-stage biotechnology company that faces various risks in its development and commercialization of novel nanoparticle-based therapies for cancer treatment, including clinical trial failures, safety concerns, and regulatory setbacks. The company also has a significant amount of debt and may need additional financing before becoming cash flow positive. While it has potential for royalties and milestone payments through its collaboration with JNJ, the success of its lead program NBTXR3 in head and neck and lung cancers may not be fully realized. Additionally, the recent $71M royalty monetization agreement with HCRx should provide some short-term funding, but the company may still face execution and financial risks in the future. Overall, there are significant concerns about the company's ability to successfully navigate these challenges and achieve commercial success, leading to a negative outlook for its stock.

Nanobiotix SA (NBTX) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nanobiotix SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nanobiotix SA (NBTX) Forecast

Analysts have given Nanobiotix SA (NBTX) a Buy based on their latest research and market trends.

According to 3 analysts, Nanobiotix SA (NBTX) has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nanobiotix SA (NBTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.